Bold claim: A new approach could change how we manage atrial fibrillation and its risk of heart failure and stroke. But here’s where it gets controversial: some experts worry about relying on a single drug or monitoring scheme without long-term real-world data. Below is a rewritten, uniquely worded version that preserves all key facts and details, expands slightly with clarifying context, and invites discussion.
XYRA Announces US Patent Grant for Using Dose-Adjusted Budiodarone to Lower Atrial Fibrillation Burden and Reduce Stroke and Heart Failure Risk
XYRA LLC has announced that the United States Patent and Trademark Office (USPTO) issued patent No. 12,551,706. The patent covers the use of dose-adjusted budiodarone to treat atrial fibrillation (AF) with monitoring designed to reduce or delay the risk of stroke and congestive heart failure. AF both can cause and worsen heart failure, and heart failure frequently leads to AF. The combination of these two common heart conditions presents significant treatment challenges and is associated with poor outcomes.
In AF, the loss of effective atrial contraction can decrease cardiac output, which has been linked to about a five-fold increase in the risk of heart failure, stroke, and death. Recent data indicate that up to 40% of hospitalized AF patients also have heart failure. Many approved AF therapies presently depress ventricular function, potentially precipitating or worsening heart failure; as a result, those drugs can be unsuitable for patients with or at risk of heart failure. There is a clear and urgent need for safe, effective, well-tolerated rhythm-control medications for AF that can be used in patients with existing heart failure and that may prevent the development of heart failure in AF patients who are at risk.
Evidence suggests that reducing AF burden (AFB), eliminating long AF episodes (LEAF), and returning to normal sinus rhythm can substantially improve symptoms and slow the progression of heart failure. With the widespread adoption of FDA-cleared wearable devices for AF monitoring, clinicians can identify patients with high AFB, LEAF, and related symptoms who are at elevated risk for complications such as stroke, heart failure progression, and conversion to permanent AF. Budiodarone has demonstrated a substantial reduction in the number and duration of AF episodes, helping restore atrial contraction and normal sinus rhythm. In another study, budiodarone did not suppress ventricular function and was well tolerated by AF patients with heart failure. Dose-adjusted budiodarone may offer a new, personalized treatment option for AF patients that helps prevent heart failure development or manage heart failure through careful, monitored dosing.
Peter Milner, MD, FACC, and XYRA’s managing member, commented, “In recent years, atrial fibrillation and heart failure have both grown substantially and are closely linked, yet many drugs used to treat AF are contraindicated in people with heart failure. Our plan is to pursue Phase 3 clinical trials to evaluate monitored, dose-adjusted budiodarone as a safe, effective rhythm-control therapy for AF, including patients with heart failure, and as a strategy to reduce the onset of heart failure in at-risk AF patients.”
About Budiodarone:
Budiodarone is currently in Phase 3 development and is described as a potentially first-in-class mixed ion-channel blocker that metabolizes via esterases and has a significantly shorter half-life than amiodarone, with no evidence of tissue accumulation in either human or animal studies. It has shown efficacy in treating AF by reducing symptoms, eliminating LEAF, lowering AF burden, and maintaining sinus rhythm.
About Atrial Fibrillation:
AF is the most common sustained cardiac arrhythmia in adults, affecting an estimated 44 million people worldwide. It increases thromboembolic risk and can impair cardiac performance and other morbidities. In many cases AF is first identified after a stroke, after the onset of left ventricular dysfunction, or incidentally. Management strategies for AF have evolved from primarily rate control to approaches that aim to restore and sustain normal sinus rhythm. Treatments include antiarrhythmic drugs (AAD), electrophysiological ablation, or a combination of both.
About XYRA LLC:
XYRA LLC is a private biopharmaceutical company focused on developing innovative therapies for cardiac rhythm disorders with high unmet need. XYRA’s mission is to elevate AF management to a level comparable with other common cardiovascular conditions such as hypertension and hyperlipidemia, utilizing titratable therapies guided by accessible monitoring to verify adherence and response, with the goal of improving outcomes.
For more information, visit: www.xyra.us
Logo: https://mma.prnewswire.com/media/2346659/5834609/Xyra_Logo.jpg
SOURCE XYRA
Investor Relations Contact: [email protected]
